Clinical Trial Update: Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea [Phase 2]

View source ↗

Summary

Phase 2 trial assessing eluxadoline (JNJ-27018966) for irritable bowel syndrome with diarrhea; results completed and posted in 2019, focusing on efficacy, safet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• eluxadoline (eluxadoline)

Snippet

Sponsor: Furiex Pharmaceuticals, Inc | Conditions: Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2019-10-22